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The number of cases of head and neck (H&N) cancer diagnosed in the UK has been
increasing in recent years. These cancers often require complex surgical treat-
ments and extensive rehabilitation. OBJECTIVES: To use data from the Hospital
Episode Statistics (HES) database to estimate the costs incurred by English NHS
hospitals due to treatment of H&N cancers, with a particular focus on oral cavity,
oropharyngeal and laryngeal cancers. METHODS: Inpatient admissions for H&N
cancer between the years 2006/07 to 2010/11 were retrospectively analysed. Data
was obtained from HES, a database covering English hospital activity, with inpa-
tient episodes aggregated into spells of care associated with a specific Healthcare
Resource Group (HRG). The HRGs were linked to costs from the UK National Tariff
in order to calculate the average annual and per patient payments for inpatient
treatment of H&N cancer, as per the NHS Payment by Results framework. Where
necessary, costs were supplemented by expert opinion and other published cost
estimates. RESULTS: Payments to NHS hospitals in England for inpatient stays due
to H&N cancer are estimated to cost on average £57.1 million per year. The main
driver of costs are the disproportionately high number of male cases, the costs of
which are £12,517,235, £13,327,351 and £16,185,743 for oral cavity, oropharyngeal
and laryngeal cancer, respectively. This translates to respective inpatient costs per
male of £5,354, £6,926, and £6,693. Despite similar costs per female inpatient, the
average annual payments for inpatient care were approximately £7,579,905,
£4,337,947 and £3,166,535, for oral cavity, oropharyngeal and laryngeal cancers.
CONCLUSIONS: Based on inpatient treatment alone, H&N cancers place a signifi-
cant economic burden on English NHS hospitals. This, however, is far less than the
total burden of treatment as a large proportion is delivered in the outpatient set-
ting. Further research is currently underway to quantify this total burden.
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OBJECTIVES: To estimate the costs associated with prostate cancer (PC) for Russia
in 2009. METHODS: We used the standard cost of illness (COI) method, relying on
the prevalence approach and adopting the viewpoint of the payers (national and
regional governments). We calculated direct medical costs (hospital and outpatient
services and drugs provided in outpatient care), non-medical costs (monetary pay-
ments in social benefits) and indirect costs (projected productivity loss due to
sickness and disability) associated with the PC in Russia in 2009. The data for
analysis was obtained from the national statistics, regional cancer and prescription
registries, expert panel interviews and literature. The costs were calculated for the
total population of PC patients in Russia. To calculate direct medical costs, we used
national reimbursement rates per unit of care (1 hospital day or 1 visit to an out-
patient oncology clinic) and regional data on prostate cancer drug costs. To access
non-medical costs, we used data on social benefits expenditures. Indirect costs
were estimated with friction costs method. RESULTS: The total costs of prostate
cancer in Russia in 2009 was 3,674 billion RUR (€89,98 mln), or 33 270 RUR (€814) as
average cost per patient per year. More than half of total cost (65,4%) occur in
patients during the 1st year after diagnosis. The direct medical costs accounted for
73,1% of total spending, direct non-medical costs – for 19,7%, and indirect costs – for
7,17%. Direct medical costs represented 86,6% of total spending in PC patients
within the 1st years after the diagnosis; during the subsequent years after the
diagnosis this number reduces to 47,8%. CONCLUSIONS: Our analysis demon-
strates that the most significant part of spending in prostate cancer overall is
related to direct medical costs during the 1st year after the diagnosis.
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OBJECTIVES:With current and increasing pressures to limit expenditure for health
care provision in many countries, a better understanding of the cost burden of
colorectal cancer (CRC), as well as specific determinants and drivers of expenditure
is needed. Cost estimates for individual patients vary widely, according to the data
source. Cost-of-illness (COI) studies are a useful tool to analyse and critically eval-
uate cost aspects of colorectal cancer. METHODS: A systematic review was con-
ducted from 2002 to 2012 to identify COI studies related to colorectal cancer,
searching the Medline, PubMed, Science Direct, Cochrane Library and the York CRD
databases. The search was in line with PRISMA guidelines. Studies that used prev-
alence-based approaches were grouped separately from those studies reporting
incidence-based estimates. RESULTS: Of the total of 11 studies, 6 studies reported
prevalence-based estimates, and 5 studies focused on incidence-based data. In the
studies included in the review, long term costs for colorectal cancer of up to 50,175$
per patient (2008 values) have been estimated. Most studies in the review have
shown that the initial and terminal phases of colorectal cancer care are the most
expensive, with the least costly phase for continuing treatment. However, one
study also highlighted that stage I CRC disease was the least costly, with stage III
the most costly of all four stages, due to the high cost impact of biological agents.
CONCLUSIONS: COI studies in colorectal cancer can identify specific components
and areas of care that are especially costly, thereby establishing attention for more
cost-effective approaches, especially relevant to the increased use of biological
agents in the field of personalized medicine. Future cost-of-illness studies would
greatly benefit from common approaches to methodology, concerning study de-
sign, description and cost component data. COI studies are an important tool for
HTA and especially health economic evaluations of personalized medicine.
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OBJECTIVES: Understand treatment patterns and quantify resource utilization of
HR HER2– ABC, with the overall aim of comparing costs and disease burden as
patients progress from hormonal therapy (HT) to chemotherapy (CT). METHODS:
Chart audit in France, Germany, The Netherlands, Belgium, and Sweden of 375
living and deceased postmenopausal female patients diagnosed with estrogen-
and/or progesterone-receptor–positive HER2– ABC in the past 4 years. Patients
were required to have progressed on 1 line of prior HT in the adjuvant or ad-
vanced setting and to have completed1 line of CT treatment (2 full cycles) in the
ABC setting. The chart audit was completed online using a standardized form
developed with the assistance of European academic physicians, pharmacy direc-
tors, and hospital administrators. Participation was sought from 12-21 oncologists
per country, except in Germany (11 oncologists and 10 gynecologists to reflect local
clinical practice). Data collection complied with European and country market re-
search regulations. RESULTS: Preliminary analyses included 265 charts (80% of
patients between 40 and 69 years of age) with one-third having de novo ABC, one-
third progressing during or within 1 year of adjuvant therapy, and one-third being
late progressors. In the first-line ABC setting, 57% received HT (nearly 90% pro-
gressed to CT in second-line), 43% CT, and 15% also targeted therapy (mostly bev-
acizumab). The switch from HT to CT was associated with a marked increase in
resource utilization and associated costs. Besides drug acquisition and administra-
tion costs, the main CT cost drivers were management for major CT side effects
(low blood cell counts, febrile neutropenia, neurotoxicity, mucositis) and side-ef-
fect–related hospitalization events (14% and 7% of all hospitalization events in
first- and second-line CT, respectively). CONCLUSIONS: Our results highlight the
increased costs and disease burden for postmenopausal HR HER2– ABC patients
treated with CT versus HT in EU countries.
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OBJECTIVES:Bevacizumab, a humanized monoclonal IgG antibody against the vas-
cular endothelial growth factor (VEGF), is reimbursed in the Czech Republic in
combination with chemotherapy for the first-line treatment of patients with met-
astatic colorectal cancer (mCRC). However, its high cost is a potentially limiting
factor. METHODS: The cost and effectiveness of bevacizumab in the real clinical
practice was retrospectively evaluated in the National comprehensive cancer cen-
ter from the perspective of health care payer. Cost data (examination, medication,
hospitalization) were collected since the initiation of bevacizumab treatment to
any tumor response (RECIST criteria - Complete Response (CR), Partial Response
(PR), Stable Disease (SD), Progressive Disease (PD)) and/or to death. Minimal fol-
low-up for all patients was 12 months. Costs were valued in CZK and converted to
EUR (€1CZK 25.78). RESULTS:A total of 218 patients with mCRC were treated with
bevacizumab in the first line treatment (132 men (60.6%); mean age 58.3 years)
between 11/2005-12/2010. The most frequent chemotherapeutic regimens were:
XELOX (55%), FOLFOX (26%), and FOLFIRI (4%). The treatment was mostly discon-
tinued due to PD (59% patients); further due to SD, PR or CR (total 8.3% patients),
adverse events (7.8% patients), surgery (5.5% patients). During our follow-up period
PD was recorded in 89% patients; 66% patients died. The mean cost per progres-
sion-free survival (median 9.1 months) was EUR 38,870.3 (CZK 1,002,076.3); the
mean cost to response PR, CR or SD was EUR 42,894.6 (CZK 1,105,823.1) after median
9.8 months of treatment. The median overall survival was 16.9 months and the
mean cost since initiation of treatment to death was EUR 50,791.3 (CZK 1,309,400.8).
CONCLUSIONS: The reimbursement of medication was the main cost driver ob-
served in our analysis. Drugs made up more than 93% to PR, CR or SD, 91% to PD and
88% to death of the total cost per patient respectively.
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OBJECTIVES: To characterize resource utilization and associated costs of patients
receiving systemic therapy outside of a clinical trial for unresectable stage III and IV
metastatic melanoma in Brazilian Healthcare System, and to compare results
across the public and private health systems.METHODS:A retrospective study was
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conducted in 12 sites in Brazil to evaluate resource utilization in unresectable stage
III and IV metastatic melanoma patients diagnosed or relapsed between 2008-2009.
Frequencies of resources utilization were assessed and multiplied by unit costs,
obtained by SIA-SUS (Outpatient Information System) for public health care costing
and by CBHPM-2005 (Brazilian Hierarchy Classification of Medical Procedures) for
private. RESULTS: Of 165 total patients eligible for the study, 119 (57 private sector
and 62 public sector) received systemic therapy outside of clinical trials and were
therefore eligible for the resource utilization analysis. Across three lines of therapy,
52.9% also received at least one surgery, and 27.7% also received radiotherapy.
While receiving systemic therapy, 29.4% were hospitalized, 13.4% had an emer-
gency room visit, 28.7% had an outpatient visit, and 10.1% had a transfusion. A
similar proportion received surgery in the private and public health sector (56.1%
and 50.0%, respectively), with mean costs USD278 (95%CI USD192-365) and USD437
(95%CI USD322-553), respectively. Hospitalizations were more common in the pri-
vate sector (45.6%) than the public sector (14.5%). The duration of hospitalization
among private patients had a mean duration of 8.7 days per month compared to 3.6
days. Mean costs of hospitalizations were USD1,697 (95%CI USD1,020-2,239) in the
private sector and USD1,332 (95%CI USD821-1,842) in the public. CONCLUSIONS: In
this real-world study in different regions in Brazil, per-patient medical costs in
advanced melanoma patients were higher in the private sector than the public
sector due to both higher unit cost per resource used and greater utilization of
hospitalization.
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OBJECTIVES: Clinical data supports the use of molecular profiling (MP) to inform
therapeutic decisions. In particular, evidence suggests the selection of pharmaco-
therapy for metastatic colon cancer (mCRC) patients could be further improved by
enhancing biomarker informed decision-making. While the clinical data is com-
pelling, our objective was to explore the economic consequences of adopting a
commercial MP approach with accompanying therapeutic recommendations
(Caris Target Now™) from a payer perspective via a detailed cost-offset model.
METHODS: Therapeutic recommendations based on a MP approach were com-
pared to current treatment patterns to determine the change in treatment mix and
associated treatment costs. Biomarker selection was based on a systematic review
of the literature and grading the evidence to support clinical benefit for a specific
treatment choice. Oncologists were interviewed to inform and validate modeled
treatment pathways based on patterns of biomarker expression in the patient’s
tumor. Biomarkers evaluated include: BRAF, KRAS, NRAS, PI3KCA, PTEN, EGFR,
TOP1, ERRC1, TS, and EML4-ALK. RESULTS: In our model, approximately 29% of
patients who test positive for response to EGFR inhibitor therapies, under current
clinical treatment protocol, have additional biomarkers with compelling data to
suggest non-responsiveness. These same patients display biomarkers indicating
potential benefit of other drugs. Biomarker-associated change in therapy as sug-
gested by MP, yielded an annual savings of $7.3k per mCRC patient. The adoption of
this MP service provided net cost-benefit; treatment costs avoided were substan-
tially higher (232%) than the testing cost. CONCLUSIONS: Molecular profiling, in-
cluding analysis of oncoproteins, gene expression and specific gene mutations,
may add significant economic value to the treatment of cancer patients by direct-
ing treatments to those most likely to respond. The cost-offsets associated with
biomarker-based therapy choice lead to more rational use of high-cost drugs. Im-
plementing therapy for mCRC based on a multi-biomarker, decision-support ap-
proach may have potential to improve patient care and decrease costs.
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OBJECTIVES: A relative value analysis (RVA) of first-line treatments for chronic
myeloide leukemia, dasatinib and imatinib, was performed from the Spanish Na-
tional Health System perspective.METHODS:A decision model was built according
to the European Leukemia Net recommendations. Response and tolerance were
assessed based on trial outcomes. The model was run for 1,000 patients initiated on
dasatinib (100mg, QD) or imatinib (400mg QD). Dose adjustments or treatment
switches for limited response or intolerance were allowed. Ten different cost levers
were identified for four sources of value (response, adverse event, adherence and
monitoring). Total cost (€, 2012) was estimated over 5-years, with an annual 3%
discount rate, by sum of the cost levers and drugs cost (ex-factory price with 7.5%
mandatory rebate). Data sources included literature, health costs database and
expert opinion. Sensitivity analyses (SA) were performed. RESULTS: The final in-
cremental total cost of dasatinib compared to imatinib, resulting from the RVA was
€3,355 per patient per year. Difference in drug cost of dasatinib is estimated to be
€11,363/patient/year compared to imatinib. Monitoring and treatment of adverse
events increased costs by €36/patient/year with dasatinib. Dasatinib, however, is
associated with savings in other costs: cases of low dose regimens saved €65/
patient/year. Switching for limited response or intolerance decreased costs by up to
€6,819 and €563/patient/year respectively, with dasatinib. Costs of non-adherence
and other additional management were reduced €466 and €132/patient/year with
dasatinib vs imatinib. The SA showed further reductions in the incremental cost of
dasatinib when longer term cost savings were included or the share of imatinib
patients after intolerance or limited response was increased. CONCLUSIONS: The
incremental drug cost of dasatinib vs imatinib €11,363 per patient/year (31%) is
reduced to €3,355/patient/year (9%) if the cost consequences of the events over 5
years are considered.
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OBJECTIVES: To conduct a cost-consequence analysis of the treatment of sub-
ependymal giant cell astrocytoma (SEGA) secondary to tuberous sclerosis complex
(TSC) with everolimus under the Brazilian public health care system (SUS) and
societal perspectives. METHODS: A cost-consequence analysis was developed to
compare the treatment of SEGA secondary to TSC with everolimus and current
treatment options, based on the Phase II trial of everolimus in the indication.
Population included patients above 3-years of age. Direct medical costs were esti-
mated from the perspective of the SUS, while direct medical and productivity costs
were estimated from a societal perspective. Model inputs for SEGA growth, hydro-
cephalus and seizure controls were based on the trial results. Use of resources and
unit costs were obtained from the national and international literature and admin-
istrative databases. Analysis included costs for managing adverse events on
everolimus treatment. Costs are expressed in 2011 Reals. Results are presented in
terms of incremental cost per patient with everolimus, considering scenarios with
and without seizure control. Time horizon was set in two years and no discount
was applied. Univariate sensitivity analysis was performed. RESULTS: The incre-
mental cost of treatment with everolimus was R$49.790/patient and R$40.131/pa-
tient from the perspectives of SUS and society, respectively. Patients treated with
everolimus did not experience complications of SEGA growth, and did not undergo
surgery to remove the SEGA. If improved seizure control is considered, the incre-
mental cost is reduced to R$48.949/patient and R$39.290/patient from SUS and
societal perspectives, respectively. Results were most sensitive to drug cost and
average dose. CONCLUSIONS: The incremental cost per patient with everolimus in
SEGA/TSC can be used as a simple instrument in the HTA process in Brazil, indi-
cating value for money in the comparison of current invasive interventions with
novel drug therapy affecting both patients and their caregivers.
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OBJECTIVES: Cervical cancer (CC) remains the leading cause of cancer death
among Colombian women. Human papillomavirus (HPV) 16 and 18 infection is
associated with CC while HPV 6 and 11 are related to genital warts (GW). Currently
are available 2 vaccines against HPV. Bivalent protects against carcinogenic geno-
types and tetravalent also protects against genotypes GW associated. We present
the cost-effectiveness evaluation of the introduction of two vaccination strategies
in Colombian women taking into account the current screening program.
METHODS: We designed a Markov model, which simulates the natural history of
CC and GW in a cohort of women. The occurrence parameters were extracted and
validated with a literature review and national databases. The costs were esti-
mated from costing of standard cases. We estimated the impact of the introduction
of bivalent and tetravalent HPV vaccines. We compared the different strategies in
a competitive scenario and built the ICERs. A sensitivity analysis was carried out.
RESULTS: In a cohort of 430,859 women followed for the entire life without vacci-
nation or screening programs 15,284 CC cases and 18,275 GW episodes may occur.
The CC would cause 4733 deaths. The screening program would prevent 3015 CC
deaths. Either vaccination alternatives prevents 1958 CC deaths additional to
screening program, and they are cost-effective when compared against non-vac-
cination. In a competitive analysis, vaccination with bivalentscrenning is domi-
nated while vaccination with tetravalentscreening is cost-effective (ICER per
DALY averted US $ 1239). The results are sensitive to changes in the parameters of
progression of neoplastic disease. CONCLUSIONS: Economic evaluation of HPV
vaccines in Colombian scenario shows that bivalent vaccination is a dominated
strategy, while tetravalent vaccination is cost-effective at a willingness to pay less
than 1 GDP per capita per DALY averted. The relative advantage of tetravalent is
due to avoided of costs and DALYs due to GW.
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OBJECTIVES: Denosumab reduced SREs versus zoledronic acid in a phase 3 trial,
but without significant differences in overall survival, disease progression, or seri-
ous adverse events. The cost-effectiveness of denosumab versus zoledronic acid in
mPC was assessed from a UK payer perspective. METHODS: A Markov model esti-
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